Ordesekimab Biosimilar – Anti-IL15 mAb – Research Grade from ProteoGenix; catalogue PX-TA1871; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Ordesekimab Biosimilar is a monoclonal antibody (mAb) designed to target interleukin-15 (IL-15), a cytokine involved in immune regulation and inflammation. It is a biosimilar version of the anti-IL15 mAb, originally developed by a pharmaceutical company for the treatment of autoimmune diseases and cancer.
The structure of Ordesekimab Biosimilar is similar to that of the original anti-IL15 mAb, consisting of two identical heavy chains and two identical light chains. These chains are linked together by disulfide bonds to form a Y-shaped molecule. The variable regions of the heavy and light chains are responsible for binding to IL-15, while the constant regions provide stability and effector functions.
Ordesekimab Biosimilar works by binding to IL-15 and preventing it from interacting with its receptors on immune cells. This disrupts the signaling pathway of IL-15, which is known to promote inflammation and contribute to the pathogenesis of autoimmune diseases and cancer.
In addition to blocking IL-15 signaling, Ordesekimab Biosimilar also has the ability to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This means that it can recruit immune cells and complement proteins to target and destroy cells expressing IL-15, such as cancer cells or activated immune cells in autoimmune diseases.
Due to its ability to target IL-15, Ordesekimab Biosimilar has potential applications in the treatment of various autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has also shown promising results in preclinical studies for the treatment of certain types of cancer, including lymphoma and leukemia.
As a research grade antibody, Ordesekimab Biosimilar can also be used in laboratory experiments to study the role of IL-15 in various diseases and to develop new therapeutic strategies. Its high specificity and potency make it a valuable tool for researchers in the field of immunology and oncology.
Ordesekimab Biosimilar is a monoclonal antibody targeting IL-15, a cytokine involved in immune regulation and inflammation. Its structure, activity, and potential applications make it a promising candidate for the treatment of autoimmune diseases and cancer. As a research grade antibody, it also has important implications for scientific research in the field of immunology and oncology. Further studies and clinical trials will be needed to fully understand the potential of Ordesekimab Biosimilar as a therapeutic agent.
ProteoGenix catalogue number PX-TA1871. For research use only.
Target: Ordesekimab Biosimilar – Anti-IL15 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Ordesekimab Biosimilar – Anti-IL15 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
